SEARCH

SEARCH BY CITATION

References

  • 1
    Ginsberg RJ, Kris K, Armstrong G. Cancer of the lung. In: Principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993. 67382.
  • 2
    Yasuda K, Ayabe H, Ide H, Uchida Y on behalf of the Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery. Jpn J Cardiothorac Surg 1998; 48: 40115.
  • 3
    Postus PE on behalf of the Lung Cancer Cooperative Group of the EORTC. The experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest 1997; 113( Suppl): 28S31S.
  • 4
    Nicolson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S915.
  • 5
    Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucane CD, O'Reilly MS, Hong WK, Fidler IJ, Putnum JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10: 13643.
  • 6
    Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 1131.
  • 7
    Mendelson J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1S13S.
  • 8
    Slamon DJ, Leyland-Jone B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 78392.
  • 9
    Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Easter Cooperative Oncology Group study 2598. J Clin Oncol 2004; 22: 11807.
  • 10
    Rosell R. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J Clin Oncol 2004; 22: 11713.
  • 11
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 81: 619.
  • 12
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 53: 1192202.
  • 13
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rush V, Fulton L, Mardis E, Kupfer D, et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci 2004; 101: 1330611.
  • 14
    Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Witsub II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutation in lung cancers. J Natl Cancer Inst 2005; 97: 33946.
  • 15
    Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Onlol 2005; 23: 85765.
  • 16
    Kasaoka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 891923.
  • 17
    Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, et al. Intragenic erbB2 kinase mutations in tumors. Nature 2004; 431; 5256.
  • 18
    Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer, 5th ed. Tokyo: Japan Lung Cancer Society, 1999. 1177.
  • 19
    Pegram M, Slamon D. Biological rationale for HER2/neu (c-erB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 5( Suppl 9): 139.
  • 20
    Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zamen M, Hoda S, McIntoch J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 237985.
  • 21
    Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PAJr. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29: 518.
  • 22
    Brabender J, Danenber KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 18505.
  • 23
    Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 1994; 3: 10913.
  • 24
    Lai WW, Chen FF, Wu M, Chow NH, Su WC, Ma MC, Su PF, Chen H, Lin MY, Tseng YL. Immunohistochemical analysis of epidermal growth factor receptor family member in stage I non-small-cell lung cancer. Ann Thorac Surg 2001; 72: 186876.
  • 25
    Fontanini G, De Laurentis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, DePlacido S, Tortora G, Bianco AR, Gullick W, Angeletti GA, et al. Evaluation of epidermal growth factor-related growth factor and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4: 2419.
  • 26
    Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinoma. Cancer Res 2005; 65: 16426.
  • 27
    Johnson DH, Arteaga CL. Gefitinib in recurrent non-small cell lung cancer: a IDEAL trial? J Clin Oncol 2003; 21: 22279.
  • 28
    Yarden Y, Sliwkowski MX. Untangling the erbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 12737.
  • 29
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 87680.
  • 30
    Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003; 278: 1543540.
  • 31
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson B, Eck EJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 78692.
  • 32
    Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004; 101: 142836.
  • 33
    Huang SF, Liu HP, Li LH, Ku Y-C, Fu Y-N, Tsai H-Y, Chen Y-T, Lin Y-F, Chang W-C, Kuo H-P, Wu Y-C, Chen Y-R, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195203.
  • 34
    Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pottier G, Sesboue R, Bronner C, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 112534.
  • 35
    Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, So JM, Lee H. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001; 61: 2799803.
  • 36
    Ko YC, Cheng LS, Lee CH, Huang JJ, Huang MS, Kao EL, Wang HZ, Lin HJ. Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 2000; 151: 1407.